Holen Sie sich die Stockscreener-App
2.57
0.39%
-0.01
Handel nachbörslich:
2.55
-0.02
-0.78%
Schlusskurs vom Vortag:
$2.58
Offen:
$2.5
24-Stunden-Volumen:
3.18M
Relative Volume:
1.36
Marktkapitalisierung:
$872.34M
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-19.38
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
-4.10%
1M Leistung:
-5.17%
6M Leistung:
-47.76%
1J Leistung:
-45.44%
1-Tages-Spanne:
$2.47
$2.61
1-Wochen-Bereich:
$2.47
$2.745
52-Wochen-Spanne:
$2.47
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.57 | 875.74M | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
225.28 | 36.12B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
68.36 | 11.62B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
40.80 | 7.50B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
86.42 | 7.23B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
39.60 | 7.08B | 11.99B | 24.18M | 234.31M | 0.2956 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
Demystifying GoodRx Holdings: Insights From 8 Analyst Reviews - Benzinga
Activity Recap: Can GoodRx Holdings Inc deliver consistent EPS growthJuly 2025 Snapshot & Fast Gain Stock Trading Tips - baoquankhu1.vn
GDRX: Jefferies Downgrades GoodRx Holdings with Significant PT R - GuruFocus
Leerink Partners Remains Bullish on GoodRx Holdings (GDRX) - MSN
Jefferies downgrades GoodRx stock to Hold on prescription segment challenges - Investing.com
Jefferies Downgrades GoodRx Holdings Inc. (GDRX) to Hold - StreetInsider
GoodRx Users Denied Nod For $32M Deal In Data Sharing Row - Law360
Valuation Update: Whats the MACD signal for GoodRx Holdings Inc2025 Market Overview & Smart Swing Trading Alerts - baoquankhu1.vn
GoodRx’s $32 Million Info-Sharing Deal Fails to Get Court Nod - Bloomberg Law News
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) last week's 6.9% decline must have disappointed individual investors who have a significant stake - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - simplywall.st
GoodRx won't be participating with TrumpRx: report - MSN
GoodRx (NASDAQ:GDRX) Upgraded at Wall Street Zen - MarketBeat
Aug Swings: What is the next catalyst for GoodRx Holdings IncJuly 2025 Drop Watch & Daily Price Action Insights - baoquankhu1.vn
Recap Report: What is the next catalyst for GoodRx Holdings IncBreakout Watch & Community Consensus Trade Alerts - baoquankhu1.vn
GoodRx CEO on TrumpRx and Surescripts Partnership - marketscreener.com
Performance Recap: Will GoodRx Holdings Inc stock deliver shareholder valueJuly 2025 Update & Consistent Return Investment Signals - Bộ Nội Vụ
Drug price tool shows pharmacy costs upfront with GoodRx savings - Stock Titan
BofA maintains underperform rating on GoodRx (GDRX) while trimming PT to $2.60 - MSN
BofA Maintains Underperform Rating on GoodRx (GDRX) While Trimming PT to $2.60 - Finviz
Citigroup Maintains Buy Rating on GoodRx (GDRX) but Lowers Price Target | GDRX Stock News - GuruFocus
Citigroup Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings (FRA:8GH) 3-Year RORE % : 57.89% (As of Sep. 2025) - GuruFocus
GoodRx Holdings (FRA:8GH) Days Inventory : 0.00 (As of Sep. 2025) - GuruFocus
Enterprise value to EBITDA ratio of GoodRx Holdings, Inc. Class A – FWB:8GH - TradingView — Track All Markets
GoodRx Holdings (FRA:8GH) EPS (Basic) : €0.09 (TTM As of Sep. 2025) - GuruFocus
GoodRx Holdings (FRA:8GH) Common Stock : €0.0 Mil (As of Sep. 2025) - GuruFocus
GoodRx Holdings (FRA:8GH) EV-to-Revenue : 1.30 (As of Jan. 09, 2026) - GuruFocus
How supply chain issues affect GoodRx Holdings Inc. stockTrade Performance Summary & Weekly Breakout Opportunity Watchlist - ulpravda.ru
Can GoodRx Holdings Inc. stock deliver strong Q4 earningsJuly 2025 Opening Moves & Free Fast Entry Momentum Trade Alerts - Улправда
What Wall Street predicts for GoodRx Holdings Inc. stock priceJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - Улправда
GoodRx Holdings (FRA:8GH) Interest Income : €13.6 Mil (TTM As of Sep. 2025) - GuruFocus
Aug Wrap: Is GoodRx Holdings Inc. stock positioned for digital transformationIPO Watch & Daily Profit Maximizing Trade Tips - Улправда
Is GoodRx Holdings Inc. stock positioned for digital transformationIPO Watch & Daily Profit Maximizing Trade Tips - ulpravda.ru
GoodRx Holdings Inc (FRA:8GH) Stock Earnings Transcripts - GuruFocus
Who's Buying or Selling GoodRx Holdings Inc (FRA:8GH) Stock Today? - GuruFocus
GoodRx Holdings (FRA:8GH) Days Sales Outstanding - GuruFocus
GoodRx Holdings (FRA:8GH) Price-to-Owner-Earnings : 26.89 (As of Jan. 09, 2026) - GuruFocus
GoodRx Holdings (FRA:8GH) Treasury Stock : €0.0 Mil (As of Sep. 2025) - GuruFocus
GoodRx Holdings (FRA:8GH) Purchase Of Business : €-30.0 Mil (TTM As of Sep. 2025) - GuruFocus
GoodRx Holdings (FRA:8GH) EPS without NRI - GuruFocus
GoodRx Holdings (FRA:8GH) EPS (Diluted) : €0.09 (TTM As of Sep. 2025) - GuruFocus
GoodRx Holdings Inc Stock Operating Data - GuruFocus
GoodRx Holdings (FRA:8GH) Issuance of Stock : €0.0 Mil (TTM As of Sep. 2025) - GuruFocus
GoodRx Holdings (FRA:8GH) Profitability Rank : 4 (As of Sep. 2025) - GuruFocus
GoodRx Holdings Inc (FRA:8GH) Stock News, Headlines & Updates - GuruFocus
GoodRx Holdings (FRA:8GH) 10-Year RORE % : 0.00% (As of Sep. 2025) - GuruFocus
Can GoodRx Holdings Inc. stock surprise with earnings upsideJuly 2025 Spike Watch & Target Return Focused Picks - Улправда
Why GoodRx Holdings Inc. stock could outperform in 2025Trade Exit Summary & Accurate Technical Buy Alerts - ulpravda.ru
Is GoodRx Holdings Inc. stock a safe buy before earningsForecast Cut & High Conviction Buy Zone Alerts - Улправда
Scan a code at Giant Eagle to unlock cheaper Ozempic and Wegovy - Stock Titan
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
2.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):